Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D.
Business Of Biotech
00:00
The Potential for a Commercialized Drug for Pulmonary Artery Hypertension
I'm curious about the, I guess, pivot. Not pivot, but adjustments perhaps is a better way to put it that ends event will consider or have to tackle as you move from commercialized drug that treats a couple of few dozen per year to one that potentially could have a market of tens of thousands. Down the road, I could see before you move on there, Dr. Simmons, I just got a follow question on on PAH. What's a potential kind of market size? It's a pretty substantial market in terms of a rare disease. Yeah. But what changes in your mindset as you move that ball downfield in terms of potential commercial preparation? Sure.
Transcript
Play full episode
